Free tool
Cell therapy stocks
We cover 4 companies grouped under the Cell therapy theme. The median market value in the group is $2.94B. Across the group, the median move over the past trading day is −2.48%. Price change over the past year runs from −27.0% to +169.2% across the middle 80 percent of the group, with a median of +11.4%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
4 of 86 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| LEGN | Legend Biotech Corporation | $4.02B | Mid cap | −40.44% |
| IOVA | Iovance Biotherapeutics, Inc. | $3.66B | Mid cap | +233.88% |
| MESO | Mesoblast Limited | $2.23B | Mid cap | +4.47% |
| VCEL | Vericel Corporation | $2.17B | Mid cap | +18.25% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.